ARTICLE | Clinical News
BioSante begins Phase II
May 16, 2001 7:00 AM UTC
BioSante (BTPH; CDNX:BAI) began a Phase II trial of its LibiGel transdermal testosterone gel to treat female sexual dysfunction (FSD) from low testosterone levels following menopause. The study will e...